The IDEAL Cholesterol
- 16 November 2005
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 294 (19) , 2492-2494
- https://doi.org/10.1001/jama.294.19.2492
Abstract
Three decades ago, the primary results of the Multiple Risk Factor Intervention Trial (MRFIT) were published in JAMA; that trial attempted to demonstrate benefits from lowering cholesterol (with diet) and managing other known risk factors for reducing cardiovascular morbidity and mortality.1 Since then, multiple trials have shown cardiovascular benefit from lowering cholesterol, especially low-density lipoprotein cholesterol (LDL-C).2,3 However, as of 1993, no trial had demonstrated a clear reduction in total mortality and, thus, debate still raged as to whether it was beneficial to reduce cholesterol.3Keywords
This publication has 17 references indexed in Scilit:
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease — Is It Time to Shift Our Goals?New England Journal of Medicine, 2005
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Circulation, 2000
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995